The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

Abstract

Strontium ranelate is a cost-effective agent for the treatment of established osteoporosis in women over the age of 65 years. Cost-effective scenarios were also found for the prevention and treatment of fractures associated with osteoporosis, in younger women with additional clinical risk factors.

Partial adherence: a new perspective on health economic assessment in osteoporosis

“…This means that a patient who has been on treatment for 2 years can expect some benefit from some fracture efficacy for a further 2 years after stopping treatment, which effectively reduces the impact of non-persistence on outcome. The impact of differing modes of action on offset time is not well characterized, though current knowledge suggests that the above assumptions are reasonable for all treatments in osteoporosis [7,[15][16][17]. Further research should improve our understanding of offset times and the possible impact of variations in mode of action.…”

“…The Markov methodology has been used to evaluate the cost-effectiveness of a variety of treatments for osteoporosis [4,7,[15][16][17]42], though the models tend to oversimplify the contribution of adherence. For example, a Markov cohort model was used to evaluate the cost-effectiveness of alendronate [7].…”

Tissue engineered bone using select growth factors: A comprehensive review of animal studies and clinical translation studies in man

“…Osteoporosis is a major cause of hip fractures with equally significant financial tolls derived from both immediate medical treatment and post-treatment aid for reduced mobility, disability and increased dependency (Keene et al, 1993;Leslie et al, 2012). There are currently over 2 million osteoporosis sufferers in the UK alone whose medical treatment of related fractures (Borgstrom et al, 2010a;Borgstrom et al, 2010b;Strom et al, 2013) is predicted to cost over £2 billion by 2020 (Burge et al, 2001). Throughout the rest of Europe, osteoporosis related fractures are estimated to cost £51 billion by 2050 (Kanis and Johnell, 2005).…”

Compositional and Material Properties of Rat Bone after Bisphosphonate and/or Strontium Ranelate Drug Treatment

“…Both bisphosphonate (BP) and Strontium ranelate (SrR) drug regimens have been shown to reduce the incidence of bone fracture in OP patients in large multicenter clinical trials (3,4), and thus, both drugs are currently indicated for the treatment of OP worldwide (5,6,7). BPs are known to conserve trabecular bone volume and micro-architecture, and therefore bone strength.…”